Chrome Extension
WeChat Mini Program
Use on ChatGLM

PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER

JOURNAL OF UROLOGY(2017)

Cited 2|Views24
No score
Abstract
You have accessJournal of UrologyBladder Cancer: Non-invasive III1 Apr 2017PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER Joan Palou, Richard Sylvester, Francesca Pisano, Steven Joniau, Kathy Vander Eeckt, Marco Oderda, Vincenzo Serretta, Stephane Larrè, Savino Di Stasi, Bas Van Rhijn, Alfred J Witjes, Anne Grotenhuis, Renzo Colombo, Alberto Briganti, Amrek Babjuk, Viktor Soukup, Per Uno Malmstrom, Jaques Irani, Nuria Malats, Jack Baniel, Roy Mano, Tommaso Cai, Eugene Cha, Peter Ardelt, John Varkarakis, Riccardo Bartoletti, Martin Sphan, Guido Dalbagni, Shahrokh F Shariat, Evangelous Xylinas, R Jeffrey Karnes, and Paolo Gontero Joan PalouJoan Palou More articles by this author , Richard SylvesterRichard Sylvester More articles by this author , Francesca PisanoFrancesca Pisano More articles by this author , Steven JoniauSteven Joniau More articles by this author , Kathy Vander EecktKathy Vander Eeckt More articles by this author , Marco OderdaMarco Oderda More articles by this author , Vincenzo SerrettaVincenzo Serretta More articles by this author , Stephane LarrèStephane Larrè More articles by this author , Savino Di StasiSavino Di Stasi More articles by this author , Bas Van RhijnBas Van Rhijn More articles by this author , Alfred J WitjesAlfred J Witjes More articles by this author , Anne GrotenhuisAnne Grotenhuis More articles by this author , Renzo ColomboRenzo Colombo More articles by this author , Alberto BrigantiAlberto Briganti More articles by this author , Amrek BabjukAmrek Babjuk More articles by this author , Viktor SoukupViktor Soukup More articles by this author , Per Uno MalmstromPer Uno Malmstrom More articles by this author , Jaques IraniJaques Irani More articles by this author , Nuria MalatsNuria Malats More articles by this author , Jack BanielJack Baniel More articles by this author , Roy ManoRoy Mano More articles by this author , Tommaso CaiTommaso Cai More articles by this author , Eugene ChaEugene Cha More articles by this author , Peter ArdeltPeter Ardelt More articles by this author , John VarkarakisJohn Varkarakis More articles by this author , Riccardo BartolettiRiccardo Bartoletti More articles by this author , Martin SphanMartin Sphan More articles by this author , Guido DalbagniGuido Dalbagni More articles by this author , Shahrokh F ShariatShahrokh F Shariat More articles by this author , Evangelous XylinasEvangelous Xylinas More articles by this author , R Jeffrey KarnesR Jeffrey Karnes More articles by this author , and Paolo GonteroPaolo Gontero More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2351AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Goals of transurethral resection of a bladder tumour (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumours is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumours. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumour factors that may influence the presence of residual disease at re-TUR. METHODS In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 75.4% had multifocal tumours, 42.7% of tumours were more than 3 cm in diameter and 25.8% had concomitant CIS. We analyse this subgroup of patients who underwent re-TUR: there was no residual disease in 267 patients (28.6%) and residual disease in 667 patients (71.4%): Ta in 378 (40.5%) and T1 in 289 (30.9%) patients. Age, gender, tumour status (primary/recurrent), previous intravesical therapy, tumour size, tumour multi-focality, presence of concomitant CIS, and muscle in the specimen were analysed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions. RESULTS The following were not risk factors for residual disease: age, gender, tumour status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumours, tumours > 3 cm, and presence of concomitant CISDue to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001. The presence of muscle in the specimen was no longer significant, p = 0.15, while the presence of CIS only remained significant in the model with tumor size, p < 0.001. CONCLUSIONS The most significant factors for a higher risk of residual disease at re-TUR in T1G3 patients are multifocal tumours and tumours more than 3 cm. Patients with concomitant CIS and those without muscle in the specimen also have a higher risk of residual disease. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e901-e902 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Joan Palou More articles by this author Richard Sylvester More articles by this author Francesca Pisano More articles by this author Steven Joniau More articles by this author Kathy Vander Eeckt More articles by this author Marco Oderda More articles by this author Vincenzo Serretta More articles by this author Stephane Larrè More articles by this author Savino Di Stasi More articles by this author Bas Van Rhijn More articles by this author Alfred J Witjes More articles by this author Anne Grotenhuis More articles by this author Renzo Colombo More articles by this author Alberto Briganti More articles by this author Amrek Babjuk More articles by this author Viktor Soukup More articles by this author Per Uno Malmstrom More articles by this author Jaques Irani More articles by this author Nuria Malats More articles by this author Jack Baniel More articles by this author Roy Mano More articles by this author Tommaso Cai More articles by this author Eugene Cha More articles by this author Peter Ardelt More articles by this author John Varkarakis More articles by this author Riccardo Bartoletti More articles by this author Martin Sphan More articles by this author Guido Dalbagni More articles by this author Shahrokh F Shariat More articles by this author Evangelous Xylinas More articles by this author R Jeffrey Karnes More articles by this author Paolo Gontero More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
More
Translated text
Key words
cancer,bladder,re-tur
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined